Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
for Renal Cell Carcinoma
Sites in Pittsburgh +6 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18 - 120
Code: NCT07049926·Phase 1, Phase 2·Recruiting·Listed Jul 2025